ArticlePLoS computational biology2009
Tumor-immune interaction, surgical treatment, and cancer recurrence in a mathematical model of melanoma.
Article in PLoS computational biology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Predicting lung cancer's metastats' locations using bioclinical model.Frontiers in medicine · 2024Article
- Mathematical modeling of BCG-based bladder cancer treatment using socio-demographics.Scientific reports · 2023Article
- Article
- A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden.Nature biomedical engineering · 2021Article
- Implications of immune-mediated metastatic growth on metastatic dormancy, blow-up, early detection, and treatment.Journal of mathematical biology · 2020Article
- Computational models of melanoma.Theoretical biology & medical modelling · 2020Review
- Systematically understanding the immunity leading to CRPC progression.PLoS computational biology · 2019Article
- Coupling tumor growth and bio distribution models.Biomedical microdevices · 2019Article
- Activation of the HGF/c-Met axis in the tumor microenvironment: A multispecies model.Journal of theoretical biology · 2018Article
- Integrating Models to Quantify Environment-Mediated Drug Resistance.Cancer research · 2017Article
- Addressing current challenges in cancer immunotherapy with mathematical and computational modelling.Journal of the Royal Society, Interface · 2017Review
- Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.Oncotarget · 2017Article
- Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates.Scientific reports · 2016Article
- Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies.Oncogene · 2015Review
- A tumor growth model with deformable ECM.Physical biology · 2014Article
- Article
- Article
- Multiple types of data are required to identify the mechanisms influencing the spatial expansion of melanoma cell colonies.BMC systems biology · 2013Article
- Senescent fibroblasts in melanoma initiation and progression: an integrated theoretical, experimental, and clinical approach.Cancer research · 2013Article
- Solitary rib recurrence of hilar cholangiocarcinoma 10 years after resection: report of a case.Clinical journal of gastroenterology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Malignant melanoma is a cancer of the skin arising in the melanocytes. We present a mathematical model of melanoma invasion into healthy tissue with an immune response. We use this model as a framework with which to investigate primary tumor invasion and treatment by surgical excision. We observe that the presence of immune cells can destroy tumors, hold them to minimal expansion, or, through the production of angiogenic factors, induce tumorigenic expansion. We also find that the tumor-immune system dynamic is critically important in determining the likelihood and extent of tumor regrowth following resection. We find that small metastatic lesions distal to the primary tumor mass can be held to a minimal size via the immune interaction with the larger primary tumor. Numerical experiments further suggest that metastatic disease is optimally suppressed by immune activation when the primary tumor is moderately, rather than minimally, metastatic. Furthermore, satellite lesions can become aggressively tumorigenic upon removal of the primary tumor and its associated immune tissue. This can lead to recurrence where total cancer mass increases more quickly than in primary tumor invasion, representing a clinically more dangerous disease state. These results are in line with clinical case studies involving resection of a primary melanoma followed by recurrence in local metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.